Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis

Nicola Richardson-Harman, Carol Lackman-Smith, Patricia S. Fletcher, Peter A. Anton, James W. Bremer, Charlene S. Dezzutti, Julie Elliott, Jean-Charles B. Grivel, Patricia Guenthner, Phalguni Gupta, Maureen Jones, Nell S. Lurain, Leonid B. Margolis, Swarna Mohan, Deena Ratner, Patricia Reichelderfer, Paula Roberts, Robin J. Shattock, James E. Cummins

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Microbicide candidates with promising in vitro activity are often advanced for evaluations using human primary tissue explants relevant to the in vivo mucosal transmission of human immunodeficiency virus type 1 (HIV-1), such as tonsil, cervical, or rectal tissue. To compare virus growth or the anti-HIV-1 efficacies of candidate microbicides in tissue explants, a novel soft-endpoint method was evaluated to provide a single, objective measurement of virus growth. The applicability of the soft endpoint is shown across several different ex vivo tissue types, with the method performed in different laboratories, and for a candidate microbicide (PRO 2000). The soft-endpoint method was compared to several other endpoint methods, including (i) the growth of virus on specific days after infection, (ii) the area under the virus growth curve, and (iii) the slope of the virus growth curve. Virus growth at the assay soft endpoint was compared between laboratories, methods, and experimental conditions, using nonparametric statistical analyses. Intra-assay variability determinations using the coefficient of variation demonstrated higher variability for virus growth in rectal explants. Significant virus inhibition by PRO 2000 and significant differences in the growth of certain primary HIV-1 isolates were observed by the majority of laboratories. These studies indicate that different laboratories can provide consistent measurements of anti-HIV-1 microbicide efficacy when (i) the soft endpoint or another standardized endpoint is used, (ii) drugs and/or virus reagents are centrally sourced, and (iii) the same explant tissue type and method are used. Application of the soft-endpoint method reduces the inherent variability in comparisons of preclinical assays used for microbicide development.

Original languageEnglish
Pages (from-to)3530-3539
Number of pages10
JournalJournal of Clinical Microbiology
Volume47
Issue number11
DOIs
Publication statusPublished - Nov 2009
Externally publishedYes

Fingerprint

Anti-Infective Agents
HIV
Viruses
Growth
HIV-1
Endpoint Determination
Palatine Tonsil
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Richardson-Harman, N., Lackman-Smith, C., Fletcher, P. S., Anton, P. A., Bremer, J. W., Dezzutti, C. S., ... Cummins, J. E. (2009). Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. Journal of Clinical Microbiology, 47(11), 3530-3539. https://doi.org/10.1128/JCM.00673-09

Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. / Richardson-Harman, Nicola; Lackman-Smith, Carol; Fletcher, Patricia S.; Anton, Peter A.; Bremer, James W.; Dezzutti, Charlene S.; Elliott, Julie; Grivel, Jean-Charles B.; Guenthner, Patricia; Gupta, Phalguni; Jones, Maureen; Lurain, Nell S.; Margolis, Leonid B.; Mohan, Swarna; Ratner, Deena; Reichelderfer, Patricia; Roberts, Paula; Shattock, Robin J.; Cummins, James E.

In: Journal of Clinical Microbiology, Vol. 47, No. 11, 11.2009, p. 3530-3539.

Research output: Contribution to journalArticle

Richardson-Harman, N, Lackman-Smith, C, Fletcher, PS, Anton, PA, Bremer, JW, Dezzutti, CS, Elliott, J, Grivel, J-CB, Guenthner, P, Gupta, P, Jones, M, Lurain, NS, Margolis, LB, Mohan, S, Ratner, D, Reichelderfer, P, Roberts, P, Shattock, RJ & Cummins, JE 2009, 'Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis', Journal of Clinical Microbiology, vol. 47, no. 11, pp. 3530-3539. https://doi.org/10.1128/JCM.00673-09
Richardson-Harman, Nicola ; Lackman-Smith, Carol ; Fletcher, Patricia S. ; Anton, Peter A. ; Bremer, James W. ; Dezzutti, Charlene S. ; Elliott, Julie ; Grivel, Jean-Charles B. ; Guenthner, Patricia ; Gupta, Phalguni ; Jones, Maureen ; Lurain, Nell S. ; Margolis, Leonid B. ; Mohan, Swarna ; Ratner, Deena ; Reichelderfer, Patricia ; Roberts, Paula ; Shattock, Robin J. ; Cummins, James E. / Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. In: Journal of Clinical Microbiology. 2009 ; Vol. 47, No. 11. pp. 3530-3539.
@article{fe800ee51a0f4e3c8afab7ba4e85d258,
title = "Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis",
abstract = "Microbicide candidates with promising in vitro activity are often advanced for evaluations using human primary tissue explants relevant to the in vivo mucosal transmission of human immunodeficiency virus type 1 (HIV-1), such as tonsil, cervical, or rectal tissue. To compare virus growth or the anti-HIV-1 efficacies of candidate microbicides in tissue explants, a novel soft-endpoint method was evaluated to provide a single, objective measurement of virus growth. The applicability of the soft endpoint is shown across several different ex vivo tissue types, with the method performed in different laboratories, and for a candidate microbicide (PRO 2000). The soft-endpoint method was compared to several other endpoint methods, including (i) the growth of virus on specific days after infection, (ii) the area under the virus growth curve, and (iii) the slope of the virus growth curve. Virus growth at the assay soft endpoint was compared between laboratories, methods, and experimental conditions, using nonparametric statistical analyses. Intra-assay variability determinations using the coefficient of variation demonstrated higher variability for virus growth in rectal explants. Significant virus inhibition by PRO 2000 and significant differences in the growth of certain primary HIV-1 isolates were observed by the majority of laboratories. These studies indicate that different laboratories can provide consistent measurements of anti-HIV-1 microbicide efficacy when (i) the soft endpoint or another standardized endpoint is used, (ii) drugs and/or virus reagents are centrally sourced, and (iii) the same explant tissue type and method are used. Application of the soft-endpoint method reduces the inherent variability in comparisons of preclinical assays used for microbicide development.",
author = "Nicola Richardson-Harman and Carol Lackman-Smith and Fletcher, {Patricia S.} and Anton, {Peter A.} and Bremer, {James W.} and Dezzutti, {Charlene S.} and Julie Elliott and Grivel, {Jean-Charles B.} and Patricia Guenthner and Phalguni Gupta and Maureen Jones and Lurain, {Nell S.} and Margolis, {Leonid B.} and Swarna Mohan and Deena Ratner and Patricia Reichelderfer and Paula Roberts and Shattock, {Robin J.} and Cummins, {James E.}",
year = "2009",
month = "11",
doi = "10.1128/JCM.00673-09",
language = "English",
volume = "47",
pages = "3530--3539",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis

AU - Richardson-Harman, Nicola

AU - Lackman-Smith, Carol

AU - Fletcher, Patricia S.

AU - Anton, Peter A.

AU - Bremer, James W.

AU - Dezzutti, Charlene S.

AU - Elliott, Julie

AU - Grivel, Jean-Charles B.

AU - Guenthner, Patricia

AU - Gupta, Phalguni

AU - Jones, Maureen

AU - Lurain, Nell S.

AU - Margolis, Leonid B.

AU - Mohan, Swarna

AU - Ratner, Deena

AU - Reichelderfer, Patricia

AU - Roberts, Paula

AU - Shattock, Robin J.

AU - Cummins, James E.

PY - 2009/11

Y1 - 2009/11

N2 - Microbicide candidates with promising in vitro activity are often advanced for evaluations using human primary tissue explants relevant to the in vivo mucosal transmission of human immunodeficiency virus type 1 (HIV-1), such as tonsil, cervical, or rectal tissue. To compare virus growth or the anti-HIV-1 efficacies of candidate microbicides in tissue explants, a novel soft-endpoint method was evaluated to provide a single, objective measurement of virus growth. The applicability of the soft endpoint is shown across several different ex vivo tissue types, with the method performed in different laboratories, and for a candidate microbicide (PRO 2000). The soft-endpoint method was compared to several other endpoint methods, including (i) the growth of virus on specific days after infection, (ii) the area under the virus growth curve, and (iii) the slope of the virus growth curve. Virus growth at the assay soft endpoint was compared between laboratories, methods, and experimental conditions, using nonparametric statistical analyses. Intra-assay variability determinations using the coefficient of variation demonstrated higher variability for virus growth in rectal explants. Significant virus inhibition by PRO 2000 and significant differences in the growth of certain primary HIV-1 isolates were observed by the majority of laboratories. These studies indicate that different laboratories can provide consistent measurements of anti-HIV-1 microbicide efficacy when (i) the soft endpoint or another standardized endpoint is used, (ii) drugs and/or virus reagents are centrally sourced, and (iii) the same explant tissue type and method are used. Application of the soft-endpoint method reduces the inherent variability in comparisons of preclinical assays used for microbicide development.

AB - Microbicide candidates with promising in vitro activity are often advanced for evaluations using human primary tissue explants relevant to the in vivo mucosal transmission of human immunodeficiency virus type 1 (HIV-1), such as tonsil, cervical, or rectal tissue. To compare virus growth or the anti-HIV-1 efficacies of candidate microbicides in tissue explants, a novel soft-endpoint method was evaluated to provide a single, objective measurement of virus growth. The applicability of the soft endpoint is shown across several different ex vivo tissue types, with the method performed in different laboratories, and for a candidate microbicide (PRO 2000). The soft-endpoint method was compared to several other endpoint methods, including (i) the growth of virus on specific days after infection, (ii) the area under the virus growth curve, and (iii) the slope of the virus growth curve. Virus growth at the assay soft endpoint was compared between laboratories, methods, and experimental conditions, using nonparametric statistical analyses. Intra-assay variability determinations using the coefficient of variation demonstrated higher variability for virus growth in rectal explants. Significant virus inhibition by PRO 2000 and significant differences in the growth of certain primary HIV-1 isolates were observed by the majority of laboratories. These studies indicate that different laboratories can provide consistent measurements of anti-HIV-1 microbicide efficacy when (i) the soft endpoint or another standardized endpoint is used, (ii) drugs and/or virus reagents are centrally sourced, and (iii) the same explant tissue type and method are used. Application of the soft-endpoint method reduces the inherent variability in comparisons of preclinical assays used for microbicide development.

UR - http://www.scopus.com/inward/record.url?scp=70449686243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449686243&partnerID=8YFLogxK

U2 - 10.1128/JCM.00673-09

DO - 10.1128/JCM.00673-09

M3 - Article

VL - 47

SP - 3530

EP - 3539

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 11

ER -